查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2018962

經導管心臟瓣膜市場：2026 年至 2032 年全球市場預測，按產品類型、瓣膜類型、輸送途徑、患者年齡層和最終用戶分類。

Transcatheter Heart Valve Market by Product Type, Valve Type, Delivery Route, Patient Age Group, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，經導管心臟瓣膜市場價值將達到 44.3 億美元，到 2026 年將成長至 49.6 億美元，到 2032 年將達到 96.4 億美元，年複合成長率為 11.74%。

主要市場統計數據
基準年 2025 44.3億美元
預計年份：2026年 49.6億美元
預測年份 2032 96.4億美元
複合年成長率 (%) 11.74%

為高階決策者提供有關現代經導管心臟瓣膜技術的重要指導，闡明關鍵的臨床、營運和商業性問題。

經導管心臟瓣膜技術正從小眾創新發展成為主流臨床策略，徹底改變了結構性心臟疾病的診斷、治療和管理方式。器械設計、影像引導和手術流程的改進降低了創傷性，並擴大了適合接受導管介入治療的患者群體。因此，醫院、專科診所、器材製造商和保險公司正在重新思考治療路徑、資金分配和長期照護模式，以優先考慮創傷性較小的結構性心臟疾病介入治療。

對推動經導管心臟瓣膜治療新範式的臨床、技術和操作方面的同步變化進行全面分析。

經導管心臟瓣膜治療的格局正受到多項平行變革的重塑，這些變革正在重新定義臨床路徑和商業模式。首先，器械的迭代創新，包括密封裙邊、重新定位機制和低輪廓輸送系統的改進，拓展了手術選擇範圍並降低了併發症發生率。其次，多重模式影像和手術規劃工具的成熟使得病患選擇和器械尺寸選擇更加精準，從而提高了手術的可預測性和治療效果。

對 2025 年美國收費政策變化將如何重塑瓣膜治療領域的供應策略、價格談判和臨床准入途徑進行詳細分析。

2025年實施的關稅調整對整個經導管心臟瓣膜生態系統造成了一系列累積壓力，影響了原料採購、零件進口以及全球製造地的經濟效益。這些政策變化促使製造商重新審視與供應商的契約，並盡可能加快本地化策略的實施。近期由此產生的一個營運影響是，旨在減少對關稅敏感零件依賴的供應鏈重組舉措有所增加，這反過來又影響了前置作業時間和庫存管理實踐。

策略性細分分析揭示了瓣膜類型、設備類別、輸送途徑、醫療保健環境和患者年齡層如何影響臨床選擇和商業化優先事項。

以瓣膜類型進行的分析突顯了每種適應症的明確臨床路徑和器械要求：主動脈瓣、二尖瓣、肺動脈瓣和三尖瓣。由於主動脈瓣手術量大且解剖結構複雜，因此該區域持續推動平台技術的迭代創新；而二尖瓣和三尖瓣區域由於瓣膜解剖結構複雜且反流病理學異常，需要採用特殊的固定和密封技術。肺動脈瓣區域的應用仍主要集中在先天性疾病和術後患者群體，在這些領域，器械的小型化和柔軟性至關重要。

對全球市場監管、報銷和臨床引入實踐的差異如何影響瓣膜技術的策略市場進入和業務擴張決策進行區域評估。

美洲、歐洲、中東和非洲以及亞太地區的市場趨勢差異顯著，每個地區都展現出其獨特的法規結構、報銷模式和臨床應用路徑。在美洲，清晰的監管政策和完善的臨床試驗基礎設施歷來促進了新型瓣膜技術的早期應用；然而，與支付方的談判動態以及保險體系的多樣性會影響報銷策略和醫院的採購流程。同時，歐洲部分地區為實現監管協調所做的努力推動了跨國臨床計畫的發展，但各國不同的醫療技術評估流程導致產品上市時間和定價結構存在差異。

對決定經導管瓣膜生態系統競爭優勢的企業策略、合作夥伴關係和創新重點進行了深入概述。

競爭格局呈現出多元化的特點，既有成熟的醫療設備製造商，也有專業零件供應商，還有不斷突破設計與交付界線的敏捷型Start-Ups。主要企業採取了差異化策略，包括專注於投資下一代密封技術、拓展其輸送系統產品組合，以及建構可滿足多種閥門尺寸和適應症需求的模組化平台。醫療設備製造商與影像、數位醫療和服務供應商之間的策略合作，正在強化整合式醫療模式，從而改善手術規劃和長期監測。

為行業領導者提供可操作且優先的策略建議，以增強臨床准入、供應彈性、商業性差異化和長期價值交付。

領導企業應優先考慮整合隨機數據與真實世界註冊研究結果，從而建立綜合證據，以支持臨床導入和與支付方的溝通。透過將臨床試驗終點與真實世界療效指標相匹配，企業可以為監管機構和支付方建立引人入勝的論證，簡化導入流程。同時，投資靈活的生產策略和供應商多元化，既能維持產能以擴大規模，又能減輕貿易政策和零件採購中斷的影響。

本報告詳細介紹了一種高度透明的調查方法，該方法旨在確保對醫療設備的性能和市場動態有可靠的洞察，包括證據整合、專家參與和檢驗過程。

本研究途徑結合了對同行評審的臨床文獻的系統性回顧、臨床試驗註冊庫的分析以及對監管指導文件的重點審查，以確定臨床背景和安全性考慮。除此證據基礎外，還對介入性心臟病專家、心臟外科醫生、採購經理和監管專家進行了定性專家訪談，以了解他們對醫療設備推廣應用障礙、培訓需求以及性能差異等方面的實際觀點。

將關鍵策略見解進行簡潔整合，以指導經營團隊決策，並使投資與永續的臨床和商業性成果保持一致。

經導管心臟瓣膜領域正日趨成熟，成為一個複雜的生態系統，器械創新、不斷發展的臨床實踐和商業策略在此交匯融合。器材設計和影像技術的進步正在擴大患者群體並最佳化治療效果，同時，監管和報銷體係也在不斷調整，以支持迭代改進和更廣泛的醫療服務。同時，貿易政策和供應鏈限制等外部壓力正在加速製造商和醫療系統採取戰略應對措施。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 經導管心臟瓣市場：依產品類型分類

  • 球囊擴張型
  • 機械膨脹型
  • 自膨脹

第9章 經導管心臟瓣膜市場：瓣膜類型

  • 主動脈瓣
  • 二尖瓣
  • 肺動脈
  • 三尖瓣

第10章 經導管心臟瓣膜市場（依輸送途徑分類）

  • 經主動脈
  • 頂端通路
  • 股動脈通路
  • 鎖骨下通路

第11章 依病患年齡層別分類的經導管心臟瓣膜市場

  • 成年患者
  • 兒童患者

第12章 經導管心臟瓣膜市場：依最終用戶分類

  • 門診手術中心及診所
  • 醫院和心臟中心

第13章 經導管心臟瓣膜市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 經導管心臟瓣膜市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 經導管心臟瓣膜市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國經導管心臟瓣膜市場

第17章：中國經導管心臟瓣膜市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 4C Medical Technologies, Inc.
  • Abbott Laboratories
  • Auto Tissue Berlin GmbH
  • Boston Scientific Corporation
  • Bracco SpA
  • Colibri Heart Valve, LLC
  • CoreMedic
  • Cryolife Inc.
  • Edwards Lifesciences Corporation
  • Foldax, Inc.
  • Hansen Medical Inc. by Auris Surgical Robotics Inc.
  • JC Medical, Inc. by Genesis Group
  • JenaValve
  • Lepu Medical Technology Co., Ltd
  • LivaNova PLC
  • Mardil Medical
  • Medtronic PLC
  • Meril Life Sciences
  • NVT AG
  • SentreHEART by AtriCure
  • Stryker Corp.
  • XELTIS
Product Code: MRR-EC2E133E334A

The Transcatheter Heart Valve Market was valued at USD 4.43 billion in 2025 and is projected to grow to USD 4.96 billion in 2026, with a CAGR of 11.74%, reaching USD 9.64 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.43 billion
Estimated Year [2026] USD 4.96 billion
Forecast Year [2032] USD 9.64 billion
CAGR (%) 11.74%

An essential orientation to contemporary transcatheter heart valve innovation that frames clinical, operational, and commercial imperatives for senior decision-makers

Transcatheter heart valve technologies have moved from niche innovation to mainstream clinical strategy, catalyzing a shift in how structural heart disease is diagnosed, treated, and managed. Improvements in device design, imaging guidance, and procedural workflows have reduced invasiveness and expanded the population eligible for catheter-based interventions. As a result, hospitals, specialty clinics, device manufacturers, and payers are reassessing treatment pathways, capital allocation, and long-term care models to align with a trajectory that favors less invasive structural interventions.

This transition has been accompanied by increased collaboration between clinical leaders, engineering teams, and commercial strategists to accelerate safe adoption while controlling costs and protecting outcomes. In addition, regulatory authorities have updated pathways to reflect iterative device improvements and to harmonize evidence requirements across jurisdictions. Clinicians are now balancing established surgical conventions with expanding percutaneous options, requiring robust clinical governance and outcome monitoring that integrates real-world evidence with randomized trial data.

Consequently, executives must understand not only the technical attributes of new valve platforms but also the economic, logistical, and clinical ecosystem changes that drive adoption. This report synthesizes those dynamics into actionable insight so stakeholders can make informed choices about product development, service delivery, and strategic partnerships in a rapidly maturing field.

Comprehensive analysis of concurrent clinical, technological, and operational shifts that are driving a new paradigm for transcatheter heart valve care delivery

The landscape of transcatheter heart valve care is being reshaped by several concurrent transformative shifts that are redefining clinical pathways and commercial models. First, iterative device innovation-encompassing refinements in sealing skirts, repositionability mechanisms, and lower-profile delivery systems-has expanded procedural options and reduced complication profiles. Second, the maturation of multimodality imaging and procedural planning tools has enabled more precise patient selection and device sizing, thereby improving procedural predictability and outcomes.

Third, care delivery models are decentralizing as ambulatory surgical centers and specialized clinics assume an increasing role in low-complexity interventions, supported by standardized protocols and enhanced peri-procedural pathways. Fourth, there is a growing focus on lifecycle management of valve recipients, with registries and digital monitoring platforms capturing longitudinal outcomes that inform both clinical practice and regulatory decision-making. Fifth, supply chain partnerships and manufacturing flexibility have become strategic imperatives, enabling companies to respond rapidly to demand shifts and device iterations while managing component sourcing risk.

Collectively, these transformations are driving new commercial partnerships, payer dialogues, and cross-functional collaborations within health systems. Stakeholders that integrate clinical evidence, operational efficiency, and strategic manufacturing will be best positioned to capture value as the field continues to evolve.

In-depth exploration of how 2025 tariff policy changes in the United States are reshaping supply strategies, pricing negotiations, and clinical access pathways in the valve sector

Tariff adjustments introduced in 2025 have introduced a set of cumulative pressures across the transcatheter heart valve ecosystem, affecting raw material sourcing, component imports, and the economics of global manufacturing footprints. These policy changes have prompted manufacturers to reassess supplier contracts and to accelerate localization strategies where feasible. The immediate operational consequence has been an uptick in supply chain redesign initiatives aimed at mitigating exposure to tariff-sensitive components, which in turn has influenced lead times and inventory practices.

In response, procurement teams have emphasized dual-sourcing and component standardization to preserve production continuity while negotiating pricing volatility. Regulatory and quality teams have also been engaged earlier in supplier qualification processes to ensure compliance with both device safety standards and evolving trade regulations. Clinically, some institutions have experienced temporary disruptions in device availability that necessitated modified scheduling practices and contingency planning to maintain patient access to timely interventions.

From a commercial perspective, increased landed costs have intensified discussions with payers around appropriate reimbursement adjustments and bundle pricing. At the same time, some manufacturers have explored value-engineering initiatives and process efficiencies to offset higher import costs without undermining clinical performance. Ultimately, the tariffs have accelerated strategic choices about manufacturing localization, supplier diversification, and commercial contracting that will have lasting implications for cost structures and market competition.

Strategic segmentation analysis revealing how valve type, device class, delivery route, care setting, and patient age groups drive clinical choice and commercialization priorities

Analysis across valve type highlights distinct clinical pathways and device requirements for aortic, mitral, pulmonary, and tricuspid indications. The aortic space continues to drive iterative platform innovation due to high procedure volumes and diverse anatomical challenges, whereas the mitral and tricuspid domains demand specialized anchoring and sealing approaches because of complex valve anatomy and regurgitant pathophysiology. Pulmonary applications remain focused on congenital and post-surgical populations where device miniaturization and flexibility are paramount.

Product type segmentation between balloon-expandable, mechanically expandable, and self-expandable technologies underpins strategic differentiation. Balloon-expandable platforms offer precise radial force characteristics suitable for calcified anatomies, mechanically expandable designs emphasize repositionability and controlled deployment, and self-expandable options provide conformability in irregular annuli and are often selected for their recapture capabilities. These technical distinctions inform clinical training requirements, inventory strategies, and post-market surveillance priorities.

Delivery route considerations across transaortic, transapical, transfemoral, and transsubclavian approaches indicate that transfemoral access remains the least invasive pathway when anatomy permits, whereas transapical and transaortic routes are reserved for complex anatomies or when peripheral access is limited. Each delivery route carries specific imaging and antithrombotic management implications that affect peri-procedural workflows.

End user segmentation that compares ambulatory surgical centers and clinics with hospitals and cardiac centers reveals divergent infrastructure needs. Ambulatory settings require streamlined instrumentation, rapid turnover protocols, and clear escalation pathways, while hospitals and cardiac centers must sustain broader multidisciplinary teams, hybrid operating environments, and comprehensive post-procedural monitoring. Finally, patient age group segmentation that distinguishes adult patients from pediatric patients drives differences in device sizing, long-term durability expectations, and lifelong follow-up strategies, with pediatric care emphasizing growth accommodation and minimization of reintervention burden.

Regional assessment of how divergent regulatory, reimbursement, and clinical adoption realities across global markets shape strategic entry and scaling decisions for valve technologies

Market behavior varies considerably across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each presenting distinct regulatory frameworks, reimbursement paradigms, and clinical adoption curves. In the Americas, regulatory clarity and established clinical trial infrastructures have historically enabled earlier adoption of novel valve technologies, while payer negotiation dynamics and heterogeneous insurance landscapes influence reimbursement strategies and hospital procurement processes. Conversely, regulatory harmonization efforts across parts of Europe have supported multi-country clinical programs, yet country-level health technology assessment processes drive differentiated adoption timing and pricing structures.

The Middle East & Africa region typically demonstrates pockets of advanced tertiary cardiac care concentrated in major urban centers, with adoption patterns influenced by public-private partnerships and medical tourism flows. In contrast, Asia-Pacific exhibits rapid procedural growth in certain markets driven by demographic trends and increasing investment in structural heart programs, although regulatory timelines and domestic manufacturing initiatives differ significantly by country.

Across regions, clinical training, registry participation, and post-market surveillance practices vary, underscoring the necessity for tailored market-entry strategies. Manufacturers and health systems must therefore align regulatory submissions, commercial models, and clinician education programs to regional norms while leveraging global evidence to accelerate local adoption.

Insightful overview of corporate strategies, alliance frameworks, and innovation priorities that are determining competitive advantage in the transcatheter valve ecosystem

The competitive environment is characterized by a mix of established device manufacturers, specialized component suppliers, and agile start-ups that are pushing the boundaries of design and delivery. Leading players have pursued differentiated strategies such as focused investments in next-generation sealing technologies, expansion of delivery system portfolios, and the establishment of modular platforms to support multiple valve sizes and indications. Strategic partnerships between device firms and imaging, digital health, and services providers have reinforced integrated care models that improve procedural planning and longitudinal monitoring.

Mergers and acquisitions, selective licensing deals, and co-development alliances have been used to accelerate capability expansion, particularly in areas such as leaflet materials, polymer science, and advanced manufacturing techniques like additive manufacturing. Concurrently, smaller innovators are concentrating on niche indications or on incremental improvements that address specific procedural complications. This dual pathway of sustained large-scale platform evolution and targeted niche innovation fosters a diverse pipeline that continues to expand clinical options.

Commercially, companies are strengthening value proposition narratives that combine clinical outcomes, cost-effectiveness analyses, and service-level guarantees to secure long-term contracts with health systems. Investment in training academies and proctor networks has become a differentiator, enabling faster adoption by offering hands-on experience and standardized procedural training. Overall, firms that integrate product excellence with robust service models and strategic partnerships will sustain competitive advantage.

Actionable and prioritized strategic recommendations for industry leaders to strengthen clinical adoption, supply resilience, commercial differentiation, and long-term value delivery

Leaders should prioritize integrated evidence generation that blends randomized data with real-world registry outcomes to support clinical adoption and payer engagement. By aligning clinical trial endpoints with real-world performance metrics, organizations can generate persuasive narratives for both regulators and payers, thereby smoothing adoption pathways. In parallel, investing in flexible manufacturing strategies and supplier diversification will mitigate exposure to trade-policy and component-sourcing disruptions while preserving capacity to scale.

Operationally, expanding clinician training infrastructures and establishing regional centers of excellence can accelerate safe adoption while ensuring consistent outcomes. These programs should be coupled with digital tools that enhance procedural planning, device sizing, and post-procedural follow-up. Commercially, negotiating outcome-based contracting and innovative reimbursement constructs can align incentives with systems that prioritize long-term patient benefit and cost containment.

Finally, executives should cultivate cross-sector partnerships that integrate device development with imaging, software, and services to provide bundled solutions that address whole-patient pathways. Prioritizing these strategic initiatives will enhance competitive positioning, reduce implementation friction, and increase the likelihood of sustained clinical and commercial success.

Transparent methodology detailing evidence synthesis, expert engagement, and validation processes used to ensure robust insights into device performance and market dynamics

The research approach combined a systematic review of peer-reviewed clinical literature, analysis of trial registries, and targeted examination of regulatory guidance documents to establish clinical context and safety considerations. This evidence base was supplemented by qualitative expert interviews with interventional cardiologists, cardiac surgeons, procurement leaders, and regulatory specialists to capture on-the-ground perspectives about adoption barriers, training needs, and device performance nuances.

Secondary sources, including technical white papers, device labeling, and procedural guideline updates, were analyzed to understand device characteristics, delivery routes, and recommended peri-procedural practices. Supply chain and manufacturing insights were derived from vendor disclosures, procurement guidelines, and public filings that illustrate sourcing models and capacity strategies. Throughout the study, evidence was triangulated to reconcile differences between clinical trial outcomes and real-world practice patterns, ensuring robust and balanced conclusions.

Quality assurance included cross-validation of interview findings against published evidence and internal peer review by multidisciplinary analysts to minimize bias. Where data gaps existed, conservative interpretation and clearly stated assumptions were used to preserve analytical integrity and to highlight areas where further study is warranted.

Concise synthesis of critical strategic takeaways to guide executive decision-making and align investments with sustainable clinical and commercial outcomes

The transcatheter heart valve domain is maturing into a complex ecosystem where device innovation, clinical practice evolution, and commercial strategy converge. Advances in device design and imaging have expanded candidate populations and optimized outcomes, while regulatory and reimbursement systems adapt to support iterative improvements and broader access. At the same time, external pressures such as trade policy and supply chain constraints are accelerating strategic responses from manufacturers and health systems alike.

Stakeholders that prioritize integrated evidence generation, flexible manufacturing, and clinician-focused training will be best positioned to convert technological advances into sustained clinical and commercial success. Moreover, coordinated engagement with payers and health systems around value-based care models will be critical to align incentives and realize broader access for eligible patients. In short, the pathway to leadership in this space requires a multidimensional strategy that combines technical excellence, operational resilience, and a clear value narrative to clinicians, payers, and hospital partners.

Collectively, these takeaways provide a framework for decision-makers to align investments, partnerships, and clinical programs so they can responsibly scale innovations that improve patient outcomes and system efficiency.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Transcatheter Heart Valve Market, by Product Type

  • 8.1. Balloon-Expandable
  • 8.2. Mechanically Expandable
  • 8.3. Self-Expandable

9. Transcatheter Heart Valve Market, by Valve Type

  • 9.1. Aortic
  • 9.2. Mitral
  • 9.3. Pulmonary
  • 9.4. Tricuspid

10. Transcatheter Heart Valve Market, by Delivery Route

  • 10.1. Transaortic
  • 10.2. Transapical
  • 10.3. Transfemoral
  • 10.4. Transsubclavian

11. Transcatheter Heart Valve Market, by Patient Age Group

  • 11.1. Adult Patients
  • 11.2. Pediatric Patients

12. Transcatheter Heart Valve Market, by End User

  • 12.1. Ambulatory Surgical Centers & Clinics
  • 12.2. Hospitals & Cardiac Centers

13. Transcatheter Heart Valve Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Transcatheter Heart Valve Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Transcatheter Heart Valve Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Transcatheter Heart Valve Market

17. China Transcatheter Heart Valve Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. 4C Medical Technologies, Inc.
  • 18.6. Abbott Laboratories
  • 18.7. Auto Tissue Berlin GmbH
  • 18.8. Boston Scientific Corporation
  • 18.9. Bracco S.p.A.
  • 18.10. Colibri Heart Valve, LLC
  • 18.11. CoreMedic
  • 18.12. Cryolife Inc.
  • 18.13. Edwards Lifesciences Corporation
  • 18.14. Foldax, Inc.
  • 18.15. Hansen Medical Inc. by Auris Surgical Robotics Inc.
  • 18.16. JC Medical, Inc. by Genesis Group
  • 18.17. JenaValve
  • 18.18. Lepu Medical Technology Co., Ltd
  • 18.19. LivaNova PLC
  • 18.20. Mardil Medical
  • 18.21. Medtronic PLC
  • 18.22. Meril Life Sciences
  • 18.23. NVT AG
  • 18.24. SentreHEART by AtriCure
  • 18.25. Stryker Corp.
  • 18.26. XELTIS

LIST OF FIGURES

  • FIGURE 1. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TRANSCATHETER HEART VALVE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TRANSCATHETER HEART VALVE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES TRANSCATHETER HEART VALVE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA TRANSCATHETER HEART VALVE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY BALLOON-EXPANDABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY BALLOON-EXPANDABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY BALLOON-EXPANDABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY MECHANICALLY EXPANDABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY MECHANICALLY EXPANDABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY MECHANICALLY EXPANDABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY SELF-EXPANDABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY SELF-EXPANDABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY SELF-EXPANDABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY AORTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY AORTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY AORTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY MITRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY MITRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY MITRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY PULMONARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY PULMONARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY PULMONARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY TRICUSPID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY TRICUSPID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY TRICUSPID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY TRANSAORTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY TRANSAORTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY TRANSAORTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY TRANSAPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY TRANSAPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY TRANSAPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY TRANSFEMORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY TRANSFEMORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY TRANSFEMORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY TRANSSUBCLAVIAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY TRANSSUBCLAVIAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY TRANSSUBCLAVIAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY HOSPITALS & CARDIAC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY HOSPITALS & CARDIAC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY HOSPITALS & CARDIAC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS TRANSCATHETER HEART VALVE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA TRANSCATHETER HEART VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA TRANSCATHETER HEART VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER HEART VALVE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE TRANSCATHETER HEART VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST TRANSCATHETER HEART VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA TRANSCATHETER HEART VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC TRANSCATHETER HEART VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN TRANSCATHETER HEART VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. GCC TRANSCATHETER HEART VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GCC TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. GCC TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. GCC TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 112. GCC TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GCC TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION TRANSCATHETER HEART VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS TRANSCATHETER HEART VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. G7 TRANSCATHETER HEART VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. G7 TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. G7 TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. G7 TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 130. G7 TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. G7 TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. NATO TRANSCATHETER HEART VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. NATO TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. NATO TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. NATO TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 136. NATO TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. NATO TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES TRANSCATHETER HEART VALVE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA TRANSCATHETER HEART VALVE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)